Revolution Medicines, Inc. (RVMD) Tops Q2 EPS by 3c

Revolution Medicines, Inc. (NASDAQ: RVMD) reported Q2 EPS of ($0.82), $0.03 better than the analyst estimate of ($0.85). Revenue for the quarter came in at $9.1 million versus the consensus estimate of $7.02 million.

For earnings history and earnings-related data on Revolution Medicines, Inc. (RVMD) click here.

You May Also Be Interested In

• Micron offers Taiwan workers up to 68-month bonuses as strike threat looms
• UBS Reiterates Buy Rating on Darden Restaurants (DRI) Ahead of Q1 Earnings
• Incyte (INCY) Reiterated at Neutral by Cantor Fitzgerald After Management Chat